Charles Romley Alder Wright several hours and produced a more potent, acetylated form of morphine, now called "diamorphine (or diacetylmorphine)", also known as heroin. After Wright's death, Heinrich Dreser, a chemist at Bayer Laboratories, continued to test heroin. Bayer marketed it as an analgesic and 'sedative for coughs' in 1898. When its addictive potential was recognized, Bayer ceased its production in 1913. In 1892, Wright was the first to report the existence of the stoichiometric intermetallic compound AlSb (aluminium antimonide), which is now recognized as a compound semiconductor with potential use in high-frequency, low-power consumption microelectronics applications, as well as gamma radiation detection. In
Bayer type of progestin hormone called drospirenone in combination with estrogen. Yaz is advertised as a treatment for premenstrual dysphoric disorder (PMDD) and moderate acne. Other key products include the cancer drug Nexavar, the multiple sclerosis drug betaferon/betaseron and the blood-clotting drug, Kogenate. In May 2014 it was announced that Bayer would buy Merck & Co's consumer health care unit for $14.2 billion. Bayer also controls Dihon Pharmaceutical Group Co., Ltd in China. The Pharmaceuticals Division focuses on prescription products, especially for women’s healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division